EX-10.1



 Exhibit 10.1 

EXECUTION VERSION 
  

 
  

HURON CONSULTING GROUP INC. 
 (a
Delaware corporation) 
 $225,000,000 

1.25% CONVERTIBLE SENIOR NOTES DUE 2019 

PURCHASE AGREEMENT 
 Dated:
September 4, 2014 
  
  

 







 HURON CONSULTING GROUP INC. 

(a Delaware corporation) 

$225,000,000 
 1.25% Convertible
Senior Notes due 2019 
 PURCHASE AGREEMENT 

September 4, 2014 
 Merrill Lynch, Pierce,
Fenner & Smith 
 Incorporated 
 J.P.
Morgan Securities LLC 
 as Representatives of the several Initial Purchasers 

c/o Merrill Lynch, Pierce, Fenner & Smith 

Incorporated 
 One Bryant Park 

New York, New York 10036 
 Ladies and Gentlemen: 

Huron Consulting Group Inc., a Delaware corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce,
Fenner & Smith Incorporated (“Merrill Lynch”) and each of the other Initial Purchasers named in Schedule A hereto (collectively, the “Initial Purchasers,” which term shall also include any initial purchaser substituted
as hereinafter provided in Section 11 hereof), for whom Merrill Lynch and J.P. Morgan Securities LLC (“J.P. Morgan”) are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale
by the Company and the purchase by the Initial Purchasers, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $225,000,000 aggregate principal amount of the Company’s 1.25% Convertible
Senior Notes due 2019 (the “Initial Securities”) and (ii) the grant by the Company to the Initial Purchasers, acting severally and not jointly, of the option to purchase all or any part of an additional $25,000,000 aggregate principal
amount of its 1.25% Convertible Senior Notes due 2019 (the “Option Securities” and, together with the Initial Securities, the “Securities”). The Securities are to be issued pursuant to an indenture, to be dated as of
September 10, 2014 (the “Indenture”), between the Company and U.S. Bank National Association as trustee (the “Trustee”). 

The Company understands that the Initial Purchasers propose to make an offering of the Securities on the terms and in the manner set forth
herein and agrees that the Initial Purchasers may resell, subject to the conditions set forth herein, all or a portion of the Securities to purchasers (“Subsequent Purchasers”) at any time after this Agreement has been executed and
delivered. The Securities are to be offered and sold through the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the “1933 Act”), in reliance upon exemptions therefrom. Pursuant to the terms
of the Securities and the Indenture, investors that acquire Securities may only resell or otherwise transfer such Securities if such Securities are hereafter registered under the 1933 Act or if an exemption from the registration requirements of
the 1933 Act is available (including the exemption afforded by Rule 144A (“Rule 144A”) of the rules and regulations promulgated under the 1933 Act (the “1933 Act Regulations”) by the Securities and Exchange
Commission (the “Commission”)). 







 The Company has prepared and delivered to each Initial Purchaser copies of a preliminary offering
memorandum dated September 3, 2014 prior to the Applicable Time (as defined below) (the “Preliminary Offering Memorandum”) and has prepared and will deliver to each Initial Purchaser, on the date hereof or the next succeeding business
day, copies of a final offering memorandum dated September 4, 2014 (the “Final Offering Memorandum”), each for use by such Initial Purchaser in connection with its solicitation of purchases of, or offering of, the Securities.
“Offering Memorandum” means, with respect to any date or time referred to in this Agreement, the most recent offering memorandum (whether the Preliminary Offering Memorandum or the Final Offering Memorandum, or any amendment or supplement
to either such document), including exhibits thereto and any documents incorporated therein by reference, which has been prepared and delivered by the Company to the Initial Purchasers, in the case of the Preliminary Offering Memorandum prior to the
Applicable Time, in connection with their solicitation of purchases of, or offering of, the Securities. The Company will prepare a final term sheet reflecting the final terms of the Securities, in the form set forth in Schedule B hereto (the
“Final Term Sheet”), and will deliver such Final Term Sheet to the Initial Purchasers prior to the Applicable Time in connection with their solicitation of purchases of, or offering of, the Securities. The Company agrees that, unless it
obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities by any written materials other than the Offering Memorandum and the Issuer Written Information. “Issuer Written Information”
means (i) any writing intended for general distribution to investors as evidenced by its being specified in Schedule C hereto, including the Final Term Sheet, and (ii) any “road show” that is a “written communication”
within the meaning of the 1933 Act. “General Disclosure Package” means the Preliminary Offering Memorandum and any Issuer Written Information specified on Schedule C hereto and issued at or prior to 8:00 A.M., New York City time, on
September 5, 2014 or such other time as agreed by the Company and Merrill Lynch (such date and time, the “Applicable Time”). 

All references in this Agreement to financial statements and schedules and other information which is “contained,”
“included” or “stated” in the Offering Memorandum (or other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which are incorporated by reference in
the Offering Memorandum; and all references in this Agreement to amendments or supplements to the Offering Memorandum shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934 (the
“1934 Act”) which is incorporated by reference in the Offering Memorandum. 
 SECTION 1. Representations and
Warranties. 
 (a) Representations and Warranties by the Company. The Company represents and warrants to each Initial Purchaser as
of the date hereof, the Applicable Time, the Closing Time and any Date of Delivery (as defined below), and agrees with each Initial Purchaser, as follows: 

(i) General Disclosure Package; Rule 144A Eligibility. The Company hereby confirms that it has authorized the use
of the General Disclosure Package, including the Preliminary Offering Memorandum and the Final Term Sheet, and the Final Offering Memorandum in connection with the offer and sale of the Securities by the Initial Purchasers. The Securities are
eligible for resale pursuant to Rule 144A and will not be, at the Closing Time, of the same class as securities of the Company listed on a national securities exchange registered under Section 6 of the 1934 Act, or quoted in a U.S.
automated interdealer quotation system. 
 (ii) No Registration Required; No General Solicitation. Subject to
compliance by the Initial Purchasers with the representations and warranties of the Initial Purchasers and the procedures set forth in Section 6 hereof, it is not necessary in connection with the offer, sale and delivery of the offered
Securities to the Initial Purchasers and to each Subsequent Purchaser who 

  
 2 








 
purchases the Securities from the Initial Purchaser in the initial resale of such Securities by the Initial Purchaser in the manner contemplated by this Agreement, the General Disclosure Package
and the Final Offering Memorandum to register the Securities under the 1933 Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended (the “1939 Act”). None of the Company, its Affiliates or any person acting
on its or any of their behalf (other than the Initial Purchasers, as to whom the Company makes no representation) has engaged, in connection with the offering of the offered Securities, in any form of general solicitation or general advertising
within the meaning of Rule 502(c) under the 1933 Act Regulations. 
 (iii) Accurate Disclosure. As of the
Applicable Time, neither (A) the General Disclosure Package nor (B) any Issuer Written Information, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or
omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Final Offering Memorandum, as of its date, at the Closing Time
or at any Date of Delivery, did not, does not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The documents incorporated or deemed to be incorporated by reference in the General Disclosure Package and the Final Offering Memorandum, when such documents incorporated by reference were filed with the Commission, when read
together with the other information in the General Disclosure Package or the Final Offering Memorandum, as the case may be, did not, does not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 The
representations and warranties in this subsection shall not apply to statements in or omissions from the General Disclosure Package or the Final Offering Memorandum made in reliance upon and in conformity with written information furnished to the
Company by any Initial Purchaser through Merrill Lynch expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading “Plan of
Distribution–Price Stabilization, Short Positions” in the Offering Memorandum (collectively, the “Initial Purchaser Information”). 

(iv) Incorporation of Documents by Reference. The documents incorporated or deemed to be incorporated by reference in
the Offering Memorandum at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and regulations of the Commission under the 1934 Act (the
“1934 Act Regulations”). 
 (v) Independent Accountants. The accountants who certified the financial
statements and supporting schedules included in the Offering Memorandum are independent public accountants with respect to the Company and its consolidated subsidiaries as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934
Act Regulations and the Public Company Accounting Oversight Board. 
 (vi) Financial Statements; Non-GAAP Financial
Measures. The financial statements included or incorporated by reference in the General Disclosure Package and the Final Offering Memorandum, together with the related schedules and notes, present fairly, in all material respects, the financial
position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial
statements have been 

  
 3 








 
prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), in all material respects, applied on a consistent basis throughout the periods involved. The
supporting schedules, if any, present fairly in accordance with GAAP the information required to be stated therein, in all material respects. The selected financial data and the summary financial information included in the Offering Memorandum
present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. No historical or pro forma financial statements or supporting
schedules are required to be included or incorporated by reference in the Offering Memorandum under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the General Disclosure Package or the Final Offering Memorandum, or
incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act and Item 10 of Regulation S-K of the 1933
Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the General Disclosure Package and the Final Offering Memorandum fairly presents the information called for in all material
respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. 
 (vii)
No Material Adverse Change in Business. Except as otherwise stated therein, since the respective dates as of which information is given in the General Disclosure Package or the Final Offering Memorandum, (A) there has been no material
adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a
“Material Adverse Effect”), (B) there have been no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its
subsidiaries considered as one enterprise, and (C) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock. 

(viii) Good Standing of the Company. The Company has been duly organized and is validly existing as a corporation in
good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the General Disclosure Package and the Final Offering Memorandum and to
enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by
reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not reasonably be expected to result in a Material Adverse Effect. 

(ix) Good Standing of Subsidiaries. Each “significant subsidiary” of the Company (as such term is defined in
Rule 1-02 of Regulation S-X) (each, a “Subsidiary” and, collectively, the “Subsidiaries”) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization,
has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the General Disclosure Package and the Final Offering Memorandum and is duly qualified to transact business and is in
good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably
be expected to result in a Material Adverse Effect. Except as otherwise disclosed in the General Disclosure Package and the Final Offering Memorandum, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and
validly issued, is fully paid and non-assessable and 

  
 4 








 
is owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital
stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the
subsidiaries listed in Exhibit 21 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. 

(x) Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in
the General Disclosure Package and the Final Offering Memorandum in the column entitled “Actual” under the caption “Capitalization” (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations,
agreements or employee benefit plans referred to in the General Disclosure Package and the Final Offering Memorandum or pursuant to the exercise of convertible securities or options referred to in the General Disclosure Package and the Final
Offering Memorandum). 
 (xi) Authorization of Agreement. This Agreement has been duly authorized, executed and
delivered by the Company. 
 (xii) Authorization of the Indenture. The Indenture has been duly authorized by the
Company and, when duly executed and delivered by the Company and the Trustee, will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be
limited by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors’ rights generally and except as enforcement thereof is
subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law). 

(xiii) Authorization of the Securities and the Common Stock. The Securities have been duly authorized and, at the
Closing Time, will have been duly executed by the Company and, when authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of the purchase price therefor as provided in this Agreement, will
constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to
fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors’ rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered
in a proceeding in equity or at law), and will be in the form contemplated by, and entitled to the benefits of, the Indenture. The shares of Common Stock issuable upon conversion of the Securities have been duly authorized and reserved for issuance
upon such conversion by all necessary corporate action and such shares, when issued upon such conversion, will be validly issued and will be fully paid and non-assessable; no holder of such shares will be subject to personal liability by reason of
being such a holder; and the issuance of such shares upon such conversion will not be subject to the preemptive or other similar rights of any securityholder of the Company. 

(xiv) Description of the Securities, the Common Stock and the Indenture. The Securities and the Indenture will conform
in all material respects to the respective statements relating thereto contained in the General Disclosure Package and the Final Offering Memorandum. The Common Stock conforms in all material respects to all statements relating thereto contained or
incorporated by reference in the General Disclosure Package and the Final Offering Memorandum and such description conforms to the rights set forth in the instruments defining the same. 

  
 5 








 (xv) Registration Rights. There are no persons with registration rights or
other similar rights to have any securities registered for sale or sold by the Company under the 1933 Act. 
 (xvi)
Absence of Violations, Defaults and Conflicts. Neither the Company nor any of its subsidiaries is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any
obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which
it or any of them may be bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults that would not, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or
other authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except for such violations that would not, singly
or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the General Disclosure Package and the
Final Offering Memorandum (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”) and compliance by the Company with its
obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment
Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts,
breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect); nor will such action result in any violation of (i) the
provisions of the charter, by-laws or similar organizational document of the Company or any of its subsidiaries or (ii) any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except, in the case of this
clause (ii), for such violations of any law, statute, rule, regulation, judgment, order, writ or decree (other than (x) federal securities laws, regulations and rules and (y) judgments, orders, writs or decrees thereunder) as would not,
singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. As used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or
any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. 

(xvii) Absence of Labor Dispute. No labor dispute with the employees of the Company or any of its subsidiaries exists
or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary’s principal suppliers, manufacturers, customers or contractors, which,
in either case, would reasonably be expected to result in a Material Adverse Effect. 

  
 6 








 (xviii) Absence of Proceedings. Except as disclosed in the General
Disclosure Package and the Final Offering Memorandum, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the
Company or any of its subsidiaries, which would, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, or which would, singly or in the aggregate, reasonably be expected to materially and adversely affect their
respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the
Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the General Disclosure Package and the Final Offering Memorandum, including ordinary routine litigation
incidental to the business, would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 

(xix) Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order,
registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the
consummation of the transactions contemplated by this Agreement or for the due execution, delivery and performance of the Indenture, except (A) such as have been already obtained, (B) such as may be required under the securities or
“Blue Sky” laws of U.S. state or non-U.S. jurisdictions or other non-U.S. laws applicable to the purchase of the Securities outside the United States in connection with the transactions contemplated hereby, (C) the filing of a current
report on Form 8-K with the Commission under the 1934 Act regarding the transactions contemplated hereby, which the Company covenants it will timely file under the 1934 Act or (D) those the failure to obtain would not, singly or in the
aggregate, reasonably be expected to (i) result in a Material Adverse Effect or (ii) materially and adversely affect the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations
hereunder. 
 (xx) Possession of Licenses and Permits. Except as would not, singly or in the aggregate, reasonably be
expected to result in a Material Adverse Effect, the Company and its subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, “Governmental Licenses”) issued by the appropriate Governmental
Entities necessary to conduct the business now operated by them. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the
aggregate, reasonably be expected to result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses
to be in full force and effect would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or
modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect. 

(xxi) Title to Property. The Company and its subsidiaries do not own any real property. The Company and its subsidiaries
have good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the General
Disclosure Package and the Final Offering Memorandum or (B) do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the
Company or any of its subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in
the General Disclosure Package and the Final Offering Memorandum, are 

  
 7 








 
in full force and effect; and neither the Company nor any such subsidiary has any notice of any claim of any sort that has been asserted by anyone adverse to the rights of the Company or any
subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease except for any
claims which would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
 (xxii)
Possession of Intellectual Property. The Company and its subsidiaries own or possess, or can acquire on reasonable terms, patents, patent rights, licenses, inventions, copyrights, know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, “Intellectual Property”) necessary
to carry on the business currently operated by them, except where such failure to own or possess, or such inability to acquire on reasonable terms, would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect;
and neither the Company nor any of its subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which
would render any Intellectual Property invalid or inadequate to protect the interest of the Company or any of its subsidiaries therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity
or inadequacy, singly or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. 
 (xxiii)
Environmental Laws. Except as described in the General Disclosure Package and the Final Offering Memorandum or would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (A) neither the Company
nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any
judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or
wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing
materials or mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”),
(B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C) there are no pending or, to the knowledge of the
Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any applicable Environmental Law against the Company
or any of its subsidiaries and (D) there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity,
against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any applicable Environmental Laws. 

(xxiv) Accounting Controls and Disclosure Controls. The Company and each of its subsidiaries maintain effective internal
control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls sufficient to
provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain 

  
 8 








 
accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the General
Disclosure Package and the Final Offering Memorandum fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the
General Disclosure Package and the Final Offering Memorandum, since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting (whether
or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The
Company and each of its subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act
Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions
regarding disclosure. 
 (xxv) Compliance with the Sarbanes-Oxley Act. There is and, since January 1, 2010, has
been, no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and
regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications. 

(xxvi) Payment of Taxes. All United States federal income tax returns of the Company and its subsidiaries required by
law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have
been provided. The United States federal income tax returns of the Company through the fiscal year ended December 31, 2012 have been settled and no assessment in connection therewith has been made against the Company. The Company and its
subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not reasonably be expected to result in a
Material Adverse Effect, and has paid all taxes shown by such returns or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves
have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments
for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect. 

(xxvii) Insurance. The Company and its subsidiaries carry or are entitled to the benefits of insurance, with insurers
that the Company reasonably believes are financially sound and reputable, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in
full force and effect. The Company has no reason to believe that it or any of its subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to 

  
 9 








 
conduct its business as now conducted and at a cost that would not result in a Material Adverse Change. Neither of the Company nor any of its subsidiaries has been denied any insurance coverage
which it has sought or for which it has applied, except for such denials that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 

(xxviii) Investment Company Act. The Company is not required, and upon the issuance and sale of the Securities as herein
contemplated and the application of the net proceeds therefrom as described in the General Disclosure Package and the Final Offering Memorandum will not be required, to register as an “investment company” under the Investment Company Act
of 1940, as amended (the “1940 Act”). 
 (xxix) Absence of Manipulation. Neither the Company nor any
Affiliate of the Company has taken, nor will the Company or any Affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act. 

(xxx) Foreign Corrupt Practices Act and Unlawful Payments. None of the Company, any of its subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries (i) has used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii) is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and
regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any
candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and
procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith; (iii) has violated or is in violation of any applicable law or regulation implementing the OECD Convention on Combating
Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law; or (iv) has made, offered,
agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its
subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. 

(xxxi) Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any
Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. 

  
 10 








 (xxxii) OFAC. None of the Company, any of its subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (“Person”) currently the subject or target of any sanctions administered or
enforced by the United States Government (including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control and the U.S. Department of State and including, without limitation, the designation as a
“specially designated national” or a “blocked person”), the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the
Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject of Sanctions, including, without limitation, Cuba, Burma (Myanmar), Iran, North Korea, Sudan and Syria (each, a “Sanctioned
Country”); and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any
activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in and will not engage in any dealings or
transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. 

(xxxiii) Lending Relationship. Except as disclosed in the General Disclosure Package and the Final Offering
Memorandum, the Company (i) does not have any material lending or other relationship with any bank or lending affiliate of any Initial Purchaser and (ii) does not intend to use any of the proceeds from the sale of the Securities to
repay any outstanding debt owed to any affiliate of any Initial Purchaser. 
 (xxxiv) Statistical and Market-Related
Data. Any statistical and market-related data included in the General Disclosure Package or the Final Offering Memorandum are based on or derived from sources that the Company believes to be reliable and accurate and, to the extent required, the
Company has obtained the written consent to the use of such data from such sources and, to the extent required, the Company has obtained the written consent to the use of such data from such sources. 

(b) Officer’s Certificates. Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the
Representatives or to counsel for the Initial Purchasers pursuant to this Agreement shall be deemed a representation and warranty by the Company to each Initial Purchaser as to the matters covered thereby. 

SECTION 2. Sale and Delivery to Initial Purchasers; Closing. 

(a) Initial Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Initial Purchaser, severally and not jointly, and each Initial Purchaser, severally and not jointly, agrees to purchase from the Company, at the price set forth in Schedule A, the aggregate
principal amount of Initial Securities set forth in Schedule A, plus any additional principal amount of Initial Securities which such Initial Purchaser may become obligated to purchase pursuant to the provisions of Section 11 hereof, subject to
such adjustments as Merrill Lynch in its discretion shall make to ensure that any sales or purchases are in authorized denominations. 

  
 11 








 (b) Option Securities. In addition, on the basis of the representations and warranties
herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Initial Purchasers, severally and not jointly, to purchase the Option Securities, at the price set forth in Schedule A. The option
hereby granted may be exercised in whole or in part from time to time upon notice by the Representatives to the Company setting forth the amount of Option Securities as to which the several Initial Purchasers are then exercising the option and the
time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date of Delivery”) shall be determined by the Representatives, but shall not be later than seven full business days after the exercise
of said option, nor in any event prior to the Closing Time, and shall be within a period of thirteen (13) days beginning from, and including, the date of the Closing Time. If the option is exercised as to all or any portion of the Option
Securities, each of the Initial Purchasers, acting severally and not jointly, will purchase that proportion of the total principal amount of Option Securities then being purchased which the number of Initial Securities set forth in Schedule A
opposite the name of such Initial Purchaser bears to the total principal amount of Initial Securities, subject in each case to such adjustments as Merrill Lynch in its discretion shall make to ensure that any sales or purchases are in authorized
denominations. 
 (c) Payment. Payment of the purchase price for, and delivery of the Initial Securities (which will be represented by
one or more definitive global Securities in book-entry form that will be deposited by or on behalf of the Company with DTCC (as defined below) or its designated custodian) shall be made at the offices of
Latham & Watkins LLP at 885 Third Avenue, New York, New York 10022, or at such other place as shall be agreed upon by the Representatives and the Company, at 9:00 A.M. (New York City time) on the third (fourth, if the pricing occurs
after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 11), or such other time not later than ten business days after such date as shall be agreed
upon by the Representatives and the Company (such time and date of payment and delivery being herein called “Closing Time”). 
 In
addition, in the event that any or all of the Option Securities are purchased by the Initial Purchasers, payment of the purchase price for, and delivery such Option Securities (which will be represented by one or more definitive global Securities in
book-entry form that will be deposited by or on behalf of the Company with DTCC (as defined below) or its designated custodian) shall be made at the above-mentioned
offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from Merrill Lynch to the Company. 

Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company, against
delivery to the Representatives for the respective accounts of the Initial Purchasers of certificates for the Securities to be purchased by them. It is understood that each Initial Purchaser has authorized the Representatives, for its account, to
accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Merrill Lynch, individually and not as Representatives, may (but shall not be
obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Initial Purchaser whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the
case may be, but such payment shall not relieve such Initial Purchaser from its obligations hereunder. 
 SECTION 3. Covenants of the
Company. The Company covenants with each Initial Purchaser as follows: 
 (a) Delivery of Offering Memorandum. The Company has
delivered to each Initial Purchaser, without charge, as many copies of the Preliminary Offering Memorandum (as amended or supplemented) thereto and documents incorporated by reference therein as such Initial Purchaser


  
 12 








 
reasonably requested, and the Company hereby consents to the use of such copies. The Company will furnish to each Initial Purchaser, without charge, such number of copies of the Final Offering
Memorandum thereto and documents incorporated by reference therein as such Initial Purchaser may reasonably request. 
 (b) Notice and
Effect of Material Events. If at any time prior to the completion of resales of the Securities by the Initial Purchasers, any event shall occur or condition shall exist as a result of which it is necessary, in the reasonable opinion of counsel
for the Initial Purchasers or for the Company, to amend or supplement the General Disclosure Package or the Final Offering Memorandum in order that the General Disclosure Package or the Final Offering Memorandum, as the case may be, will not include
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a Subsequent Purchaser, the Company
will promptly (A) give the Representatives notice of such event and (B) prepare any amendment or supplement as may be necessary to correct such statement or omission and, a reasonable amount of time prior to any proposed use or
distribution, furnish the Representatives with copies of any such amendment or supplement; provided that the Company shall not use or distribute any such amendment or supplement to which the Representatives or counsel for the Initial Purchasers
shall object. The Company will furnish to the Initial Purchasers such number of copies of such amendment or supplement as the Initial Purchasers may reasonably request. 

(c) Reporting Requirements. Until the completion of the initial resales of the Securities by the Initial Purchasers, the Company will
file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and the 1934 Act Regulations. The Company has given the Representatives notice of any filings made pursuant to the
1934 Act or 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the
Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Initial Purchasers shall
reasonably object. 
 (d) Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Initial Purchasers,
to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required
to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in
which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. 

(e) Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified in the
General Disclosure Package and the Final Offering Memorandum under “Use of Proceeds.” 
 (f) DTCC. The Company will
cooperate with the Initial Purchasers and use its reasonable efforts to permit the offered Securities to be eligible for clearance and settlement through the facilities of The Depository Trust & Clearing Corporation (“DTCC”). 

(g) Listing. For so long as the Company’s Common Stock is then listed on the Nasdaq Global Select Market, the Company will use its
best efforts to effect and maintain the listing of the Common Stock issuable upon conversion of the Securities on the Nasdaq Global Select Market. 

  
 13 








 (h) Restriction on Sale of Securities. During a period of 60 days from the date of the
Final Offering Memorandum, the Company will not, without the prior written consent of Merrill Lynch and J.P. Morgan, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement
under the 1933 Act with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common
Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the
Securities to be sold hereunder, (B) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the General Disclosure Package and
the Final Offering Memorandum or (C) any shares of Common Stock issued, options to purchase Common Stock granted or other equity incentive awards granted pursuant to existing employee benefit plans of the Company referred to in the General
Disclosure Package and the Final Offering Memorandum, and any shares of Common Stock issued in respect of such awards. 
 SECTION 4.
Payment of Expenses. 
 (a) Expenses. The Company will pay or cause to be paid all expenses incident to the performance of
their obligations under this Agreement, including (i) preparation, issuance and delivery of the Securities to the Initial Purchasers and the Common Stock issuable upon conversion thereof and any charges of DTCC in connection therewith,
(ii) the fees and disbursements of the Company’s counsel, accountants and other advisors, (iii) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(d) hereof, including filing
fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection therewith and in connection with the preparation of the Blue Sky Survey and any supplement thereto in the amount of $10,000, (iv) the
preparation, printing and delivery to the Initial Purchasers of copies of each Preliminary Offering Memorandum, any Issuer Written Information, the Final Term Sheet and the Final Offering Memorandum and any amendments or supplements thereto and any
costs associated with electronic delivery of any of the foregoing by the Initial Purchasers to investors, (v) all fees and expenses of the Trustee and any expenses of any transfer agent or registrar for the Securities or the Common Stock
issuable upon conversion of the Securities, (vi) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities, including without limitation,
expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged by the Company in connection with the road show presentations, travel and lodging expenses of the representatives and officers of
the Company and any such consultants, and the cost of aircraft and other transportation chartered by the Company in connection with the road show, (vii) the fees and expenses incurred in connection with the listing of the Common Stock issuable
upon conversion of the Securities on the Nasdaq Global Select Market and (viii) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the
reforming of any contracts for sale of the Securities made by the Initial Purchasers caused by a breach of the representation contained in the first sentence of Section 1(a)(iii). 

(b) Termination of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of
Section 5, Section 10(a)(i) or (iii) or Section 11 hereof, the Company shall reimburse the Initial Purchasers for all of their reasonable, documented
out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Initial Purchasers. 

  
 14 








 SECTION 5. Conditions of Initial Purchasers’ Obligations. The obligations of the
several Initial Purchasers hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries, to the performance by the Company of
its covenants and other obligations hereunder, and to the following further conditions: 
 (a) Opinion of Counsel for Company. At the
Closing Time, the Representatives shall have received the favorable opinion and negative assurance letter, each dated the Closing Time, of McDermott Will & Emery LLP, counsel for the Company, in form and substance satisfactory to counsel
for the Initial Purchasers, together with signed or reproduced copies of such letters for each of the other Initial Purchasers, to the effect set forth in Exhibits A-1 and A-2, respectively, hereto and to such further effect as counsel to the
Initial Purchasers may reasonably request. 
 (b) Opinion of Counsel for Initial Purchasers. At the Closing Time, the Representatives
shall have received the favorable opinion, dated the Closing Time, of Latham & Watkins LLP, counsel for the Initial Purchasers, together with signed or reproduced copies of such letter for each of the other Initial Purchasers in form and
substance satisfactory to the Representatives. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware
and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem
proper, upon certificates of officers and other representatives of the Company and its subsidiaries and certificates of public officials. 

(c) Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as
of which information is given in the General Disclosure Package or the Final Offering Memorandum, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its
subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the Chief Executive Officer of the Company and of the chief financial or chief
accounting officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties of the Company in this Agreement are true and correct with the same
force and effect as though expressly made at and as of the Closing Time and (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time. 

(d) Accountant’s Comfort Letter. At the time of the execution of this Agreement, the Representatives shall have received from
PricewaterhouseCoopers LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Initial Purchasers containing statements and information
of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Offering Memorandum. 

(e) Bring-down Comfort Letter. At the Closing Time, the Representatives shall have received from PricewaterhouseCoopers LLP a letter,
dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (d) of this Section, except that the specified date referred to shall be a date not more than three business days
prior to the Closing Time. 
 (f) Listing. The Company shall have timely filed a Notification of Listing of Additional Shares with the
Nasdaq Stock Market for the listing of the Common Stock issuable upon conversion of the Securities and shall have received no objection thereto from The Nasdaq Stock Market. 

  
 15 








 (g) Lock-up Agreements. At the date of this Agreement, the Representatives shall have
received an agreement substantially in the form of Exhibit B hereto signed by the persons listed on Schedule D hereto. 
 (h)
Ratings. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any “nationally recognized statistical rating agency” (as that term is defined under Section 3(a)(62) of the 1934
Act). 
 (i) Conditions to Purchase of Option Securities. In the event that the Initial Purchasers exercise their option provided in
Section 2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries
hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received: 

(i) Officers’ Certificate. A certificate, dated such Date of Delivery, of the Chief Executive Officer of the
Company and of the chief financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(c) hereof remains true and correct as of such Date of Delivery. 

(ii) Opinion of Counsel for Company. If requested by the Representatives, the favorable opinion and negative assurance
letter of McDermott Will & Emery LLP, counsel for the Company, in form and substance satisfactory to counsel for the Initial Purchasers, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery
and otherwise to the same effect as the opinion and negative assurance letter required by Section 5(a) hereof. 
 (iii)
Opinion of Counsel for Initial Purchasers. If requested by the Representatives, the favorable opinion of Latham & Watkins LLP, counsel for the Initial Purchasers, dated such Date of Delivery, relating to the Option Securities to be
purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(b) hereof. 

(iv) Bring-down Comfort Letter. If requested by the Representatives, a letter from PricewaterhouseCoopers LLP, in form
and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section 5(d) hereof, except that the “specified
date” in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery. 

(j) Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel for the Initial Purchasers shall have been
furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory
in form and substance to the Representatives and counsel for the Initial Purchasers. 
 (k) Termination of Agreement. If any condition
specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the
obligations of the several Initial Purchasers to purchase the relevant Option Securities, may be terminated by the 

  
 16 








 
Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any
other party except as provided in Section 4 and except that Sections 1, 7, 8, 9, 14, 15, 16 and 17 shall survive any such termination and remain in full force and effect. 

SECTION 6. Subsequent Offers and Resales of the Securities. 

(a) Offer and Sale Procedures. Each of the Initial Purchasers and the Company hereby establish and agree to observe the following
procedures in connection with the offer and sale of the Securities: 
 (i) Offers and Sales. Offers and sales
of the Securities shall be made to such persons and in such manner as is contemplated by the Offering Memorandum. Each Initial Purchaser severally agrees that it will not offer, sell or deliver any of the Securities in any jurisdiction outside the
United States except under circumstances that will result in compliance with the applicable laws thereof, and that it will take at its own expense whatever action is required to permit its purchase and resale of the Securities in such jurisdictions.
The Company has not entered into any contractual arrangement, other than this Agreement, with respect to the distribution of the Securities or the Common Stock issuable upon conversion of the Securities and the Company will not enter into any such
arrangement except as contemplated thereby. 
 (ii) No General Solicitation. No general solicitation or general
advertising (within the meaning of Rule 502(c) under the 1933 Act Regulations) will be used in the United States in connection with the offering or sale of the Securities. 

(iii) Legends. Each of the Securities will bear, to the extent applicable, the legend contained in “Notice to
Investors” in the General Disclosure Package and the Final Offering Memorandum for the time period and upon the other terms stated therein. 

(iv) Minimum Principal Amount. No sale of the Securities to any one Subsequent Purchaser will be for less than U.S.
$1,000 principal amount and no Security will be issued in a smaller principal amount. 
 (b) Covenants of the Company. The Company
covenants with each Initial Purchaser as follows: 
 (i) Integration. The Company agrees that it will not and will
cause its Affiliates not to, directly or indirectly, solicit any offer to buy, sell or make any offer or sale of, or otherwise negotiate in respect of, securities of the Company of any class if, as a result of the doctrine of “integration”
referred to in Rule 502 under the 1933 Act Regulations, such offer or sale would render invalid (for the purpose of (i) the sale of the offered Securities by the Company to the Initial Purchasers, (ii) the resale of the offered
Securities by the Initial Purchasers to Subsequent Purchasers or (iii) the resale of the offered Securities by such Subsequent Purchasers to others) the exemption from the registration requirements of the 1933 Act provided by
Section 4(a)(2) thereof or by Rule 144A thereunder or otherwise. 
 (ii) Rule 144A Information. The Company
agrees that, in order to render the offered Securities eligible for resale pursuant to Rule 144A, while any of the offered Securities remain outstanding and are “restricted securities” within the meaning of Rule 144(a)(3) under
the 1933 Act, it will make available, upon request, to any holder of offered Securities or prospective purchasers of Securities the information specified in Rule 144A(d)(4), unless the Company furnishes information to the Commission pursuant to
Section 13 or 15(d) of the 1934 Act. 

  
 17 








 (iii) Restriction on Repurchases. Until the expiration of one year after
the original issuance of the offered Securities, the Company will not, and will cause its Affiliates not to, resell any offered Securities which are reacquired by such persons which are “restricted securities” (as such term is defined
under Rule 144(a)(3)), whether as beneficial owner or otherwise (except as agent acting as a securities broker on behalf of and for the account of customers in the ordinary course of business in unsolicited broker’s transactions). 

(c) Representations, Warranties and Agreements of the Initial Purchasers. Each Initial Purchaser severally and not jointly represents
and warrants to, and agrees with, the Company that it is a Qualified Institutional Buyer and an “accredited investor” within the meaning of Rule 501(a) under the 1933 Act Regulations. Each Initial Purchaser understands that the
offered Securities have not been and will not be registered under the 1933 Act and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of
the 1933 Act. Each Initial Purchaser severally represents and agrees that it has not offered or sold, and will not offer or sell, any offered Securities constituting part of its allotment within the United States except in accordance with
Rule 144A or another applicable exemption from the registration requirements of the 1933 Act. Accordingly, neither it nor any person acting on its behalf has made or will make offers or sales of the Securities in the United States by means
of any form of general solicitation or general advertising (within the meaning of Regulation D) in the United States. Each Initial Purchaser will take reasonable steps to inform, and cause each of its affiliates (as such term is defined in Rule
501(b) under the 1933 Act Regulations (each, an “Affiliate”)) to take reasonable steps to inform, persons acquiring Securities from such Initial Purchaser or Affiliate, as the case may be, in the United States that the Securities
(A) have not been and will not be registered under the 1933 Act, (B) are being sold to them without registration under the 1933 Act in reliance on Rule 144A or in accordance with another exemption from registration under the
1933 Act, as the case may be, and (C) may not be offered, sold or otherwise transferred except (1) to the Company, (2) outside the United States in accordance with Regulation S or (3) inside the United States in
accordance with (x) Rule 144A to a person whom the seller reasonably believes is a Qualified Institutional Buyer that is purchasing such Securities for its own account or for the account of a Qualified Institutional Buyer to whom notice is
given that the offer, sale or transfer is being made in reliance on Rule 144A or (y) pursuant to another available exemption from registration under the 1933 Act. 

SECTION 7. Indemnification. 

(a) Indemnification of Initial Purchasers. The Company agrees to indemnify and hold harmless each Initial Purchaser, its Affiliates, its
selling agents and their respective officers and directors and each person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows: 

(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement
or alleged untrue statement of a material fact included in any Preliminary Offering Memorandum, the Final Offering Memorandum, the information contained in the Final Term Sheet, any Issuer Written Information, any “road show” (as defined
in Rule 433 under the 1933 Act) not constituting Issuer Written Information or any other information used by or on behalf of the Company in connection with the offer or sale of the Securities (or any amendment or supplement to the foregoing) or the
omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

  
 18 








 (ii) against any and all loss, liability, claim, damage and expense whatsoever,
as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission; provided that (subject to Section 7(d) below) any such settlement is effected with the written consent of the Company; and 

(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by Merrill
Lynch), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under clauses (i) or (ii) above; 

provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in any Preliminary Offering Memorandum, the Final Offering Memorandum or the information contained in the Final Term Sheet (or any amendment or supplement to the foregoing) in
reliance upon and in conformity with the Initial Purchaser Information. 
 (b) Indemnification of Company, Directors and Officers.
Each Initial Purchaser severally agrees to indemnify and hold harmless the Company, its directors, its officers and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934
Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or
omissions, made in any Preliminary Offering Memorandum, the Final Offering Memorandum or the information contained in the Final Term Sheet (or any amendment or supplement to the foregoing) in reliance upon and in conformity with the Initial
Purchaser Information. 
 (c) Actions against Parties; Notification. Each indemnified party shall give notice as promptly as
reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability
hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant
to Section 7(a) above, counsel to the indemnified parties shall be selected by Merrill Lynch, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to the indemnified parties shall be selected by the Company. In
no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar
or related actions in the same jurisdiction arising out of the same general allegations or circumstances, unless the indemnifying party and the indemnified party shall have mutually agreed to the contrary. An indemnifying party may participate at
its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. Any indemnified party shall have the
right to retain its own counsel in any such action, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the
contrary; (ii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party; (iii) the indemnified party shall have reasonably concluded that there may be legal defenses
available to it that are different from or in addition to those available to the indemnifying party; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified
party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them. No indemnifying party shall, without the prior written 


  
 19 








 
consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 7 or Section 8 hereof (whether or not the indemnified parties are actual or potential parties
thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a
statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
 (d) Settlement
without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable
for any settlement of the nature contemplated by Section 7(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request,
(ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in
accordance with such request prior to the date of such settlement. 
 SECTION 8. Contribution. If the indemnification provided for in
Section 7 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and
the Initial Purchasers, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Initial Purchasers, on the other hand, in connection with the statements or omissions which resulted in such
losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. 
 The relative benefits received
by the Company, on the one hand, and the Initial Purchasers, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the
offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Initial Purchasers, on the other hand, bear to the aggregate initial
offering price of the Securities as set forth on the cover of the Final Offering Memorandum. 
 The relative fault of the Company, on the
one hand, and the Initial Purchasers, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates
to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

The Company and the Initial Purchasers agree that it would not be just and equitable if contribution pursuant to this Section 8 were
determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 8.
The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 8 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified
party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or
omission or alleged omission. 

  
 20 








 Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to
contribute any amount in excess of the amount by which the total price at which the Securities purchased by it and distributed to the public were offered to the public exceeds the amount of any damages that such Initial Purchaser has otherwise been
required to pay by reason of any such untrue or alleged untrue statement or omission or alleged omission. 
 No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

For purposes of this Section 8, each person, if any, who controls an Initial Purchaser within the meaning of Section 15 of the 1933
Act or Section 20 of the 1934 Act and each Initial Purchaser’s Affiliates and selling agents shall have the same rights to contribution as such Initial Purchaser, and each director of the Company, each officer of the Company, and each
person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Initial Purchasers’ respective obligations to
contribute pursuant to this Section 8 are several in proportion to the aggregate principal amount of Initial Securities set forth opposite their respective names in Schedule A hereto and not joint. 

SECTION 9. Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Initial Purchaser
or its Affiliates or selling agents, any person controlling any Initial Purchaser, its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities. 

SECTION 10. Termination of Agreement. 

(a) Termination. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time
(i) if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the General Disclosure Package or the Final Offering Memorandum, any
material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business,
or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or
development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to
proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or the Nasdaq Global Select
Market, or (iv) if trading generally on the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been
required, by any of said exchanges or by order of the Commission, the Financial Industry Regulatory Authority, Inc. or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or
clearance services in the United States, or (vi) if a banking moratorium has been declared by either Federal or New York authorities. 

  
 21 








 (b) Liabilities. If this Agreement is terminated pursuant to this Section, such
termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 7, 8, 9, 14, 15, 16 and 17 shall survive such termination and remain in full force and effect.

 SECTION 11. Default by One or More of the Initial Purchasers. If one or more of the Initial Purchasers shall fail at the Closing
Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 36 hours thereafter, to make
arrangements for one or more of the non-defaulting Initial Purchasers, or any other initial purchasers, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon
and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 36-hour period, then: 

(i) if the number of Defaulted Securities does not exceed 10% of the aggregate principal amount of the Securities to be
purchased on such date, each of the non-defaulting Initial Purchasers shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting
obligations hereunder bear to the underwriting obligations of all non-defaulting Initial Purchasers, or 

(ii) if the number of Defaulted Securities exceeds 10% of the aggregate principal amount of the Securities to be purchased on
such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Initial Purchasers to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of
Delivery, shall terminate without liability on the part of any non-defaulting Initial Purchaser. 

No action taken pursuant to this Section shall relieve any defaulting Initial Purchaser from liability in respect of its default. 

In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after
the Closing Time, which does not result in a termination of the obligation of the Initial Purchasers to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i) Representatives or (ii) the Company
shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the General Disclosure Package or the Final Offering Memorandum or
in any other documents or arrangements. As used herein, the term “Initial Purchaser” includes any person substituted for an Initial Purchaser under this Section 11. 

SECTION 12. Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to the Initial Purchasers shall be directed to Merrill Lynch at One Bryant Park, New York, New York 10036, attention of Syndicate Department (facsimile: (646) 855-3073),
with a copy to ECM Legal (facsimile: (212) 230-8730); notices to the Company shall be directed to it at 550 W. Van Buren Street, Chicago, Illinois 60607, Attention: General Counsel, with a copy to McDermott Will & Emery LLP,
227 W. Monroe Street, Chicago, Illinois 60606, Attention: Eric Orsic (facsimile: (312) 984-7700). 

SECTION 13. No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the initial offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and
the several Initial Purchasers, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each 

  
 22 








 
Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its subsidiaries or their respective stockholders, creditors, employees or
any other party, (c) no Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such
Initial Purchaser has advised or is currently advising the Company or any of its subsidiaries on other matters) and no Initial Purchaser has any obligation to the Company with respect to the offering of the Securities except the obligations
expressly set forth in this Agreement, (d) the Initial Purchasers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e) the Initial Purchasers
have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.

 SECTION 14. Parties. This Agreement shall each inure to the benefit of and be binding upon the Initial Purchasers and the Company
and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Initial Purchasers and the Company and their respective successors and the
controlling persons and officers and directors referred to in Sections 7 and 8 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained.
This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Initial Purchasers and the Company and their respective successors, and said controlling persons and officers and directors and
their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor by reason merely of such purchase. 

SECTION 15. Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and
Affiliates) and each of the Initial Purchasers hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. 
 SECTION 16. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO
THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK. 
 SECTION 17. Consent to
Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America
located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party
irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.
Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or
other proceeding brought in any such court has been brought in an inconvenient forum. 
 SECTION 18. TIME. TIME SHALL BE OF THE
ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. 

  
 23 








 SECTION 19. Counterparts. This Agreement may be executed in any number of counterparts,
each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or any other electronic
transmission shall be effective as delivery of a manually executed counterpart hereof. 
 SECTION 20. Effect of Headings. The Section
headings herein are for convenience only and shall not affect the construction hereof. 

  
 24 








 If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Initial Purchasers and the Company in accordance with its terms. 

 

			
	Very truly yours,
	
	HURON CONSULTING GROUP INC.
		
	By:	 	/s/ C. Mark Hussey
		 	Name: C. Mark Hussey
		 	Title: EVP, COO & CFO


  

			
	CONFIRMED AND ACCEPTED,
	 as of the date first above written:

	
	MERRILL LYNCH, PIERCE, FENNER & SMITH
	INCORPORATED
		
	By:	 	/s/ Clemence Rasigni
		 	Name: Clemence Rasigni
		 	Title: Managing Director
	
	J.P. MORGAN SECURITIES LLC
		
	By:	 	/s/ Sudheer Tegulapalle
		 	Name: Sudheer Tegulapalle
		 	Title: Executive Director

 For themselves and as Representatives of the other Initial Purchasers named in Schedule A hereto. 

  
 25 








 SCHEDULE A 

The initial offering price of the Securities shall be 100.00% of the principal amount thereof, plus accrued interest, if any, from the date of issuance. 

The purchase price to be paid by the Initial Purchasers for the Securities shall be 97.25% of the principal amount thereof. 

The interest rate on the Securities shall be 1.25% per annum. 
  

					
	 Name of Initial Purchaser
	  	Principal
Amount of
Securities	 
	 Merrill Lynch, Pierce, Fenner & Smith
Incorporated
	  	$	135,000,000	  
	 J.P. Morgan Securities LLC
	  	 	45,000,000	  
	 RBS Securities Inc.
	  	 	13,500,000	  
	 BMO Capital Markets Corp
	  	 	9,000,000	  
	 KeyBanc Capital Markets Inc.
	  	 	9,000,000	  
	 PNC Capital Markets LLC
	  	 	9,000,000	  
	 BBVA Securities Inc.
	  	 	4,500,000	  
		  	  
	  
	 
	 Total
	  	$	225,000,000	 
		  	  
	  
	 








 SCHEDULE B 

Final Term Sheet 
 [Insert
Final Term Sheet] 

  
 Sch B - 1 








 Pricing Term Sheet, dated September 4, 2014 

to Preliminary Offering Memorandum, dated September 3, 2014 

Strictly Confidential 
  





 
 HURON CONSULTING GROUP INC. 

$225,000,000 PRINCIPAL AMOUNT OF 

1.25% CONVERTIBLE SENIOR NOTES DUE 2019 

The information in this pricing term sheet supplements the preliminary offering memorandum, dated September 3, 2014, of Huron Consulting Group Inc. (the
“Preliminary Offering Memorandum”), and supersedes the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum. In all other respects, this pricing term
sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum, including all documents incorporated by reference therein. Terms used herein but not defined herein shall have the respective meanings set forth in the
Preliminary Offering Memorandum. All references to dollar amounts are references to U.S. dollars. 
  

			
	Issuer:	  	Huron Consulting Group Inc., a Delaware corporation.
		
	Ticker/Exchange for Common Stock:	  	HURN/The NASDAQ Global Select Market.
		
	Securities:	  	1.25% Convertible Senior Notes due 2019 (the “notes”).
		
	Principal Amount:	  	$225,000,000 (or $250,000,000 if the initial purchasers fully exercise their option to purchase additional notes).
		
	Denominations:	  	$1,000 and integral multiples of $1,000 in excess thereof.
		
	Maturity:	  	October 1, 2019, unless earlier repurchased by us or converted.
		
	No Optional Redemption:	  	We may not redeem the notes prior to maturity.
		
	Fundamental Change:	  	If we undergo a “fundamental change” (as defined in the Preliminary Offering Memorandum under the caption “Description of Notes—Fundamental Change Permits Holders to Require Us to Purchase Notes”),
subject to certain conditions, holders may require us to repurchase for cash all or a part of their notes in principal amounts of $1,000 or an integral multiple thereof. The fundamental change repurchase price will be equal to 100% of the principal
amount of the notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
		
	Interest:	  	 1.25% per year.
  

Interest will accrue from, and including, September 10, 2014, and will be payable semiannually in arrears on April 1 and October 1 of each year, beginning on
April 1, 2015. We will pay additional interest, if any, at our election as the sole remedy relating to our failure to comply with our reporting obligations as described in the Preliminary Offering Memorandum under the caption “Description of
Notes—Events of Default” and under the circumstances described in the Preliminary Offering Memorandum under the caption “Description of Notes—No Registration Rights; Additional Interest.”

		
	Settlement:	  	Cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, as described in the Preliminary Offering Memorandum under the caption “Description of Notes—Conversion
Rights—Settlement Upon Conversion.”
		
	Regular Record Dates:	  	March 15 and September 15 of each year.









			
		
	Issue Price:	  	100% of principal, plus accrued interest, if any.
		
	NASDAQ Last Reported Sale Price of our Common Stock on September 4, 2014:	  	 $62.66 per share.

		
	Initial Conversion Rate:	  	12.5170 shares of our common stock per $1,000 principal amount of notes.
		
	Initial Conversion Price:	  	Approximately $79.89 per share of our common stock.
		
	Conversion Premium:	  	Approximately 27.5% above the NASDAQ last reported sale price of our common stock on September 4, 2014.
		
	Joint Book-Running Managers:	  	 Merrill Lynch, Pierce, Fenner & Smith

Incorporated
 J.P. Morgan Securities
LLC

		
	Senior Co-Manager:	  	RBS Securities Inc.
		
	Co-Managers:	  	 BMO Capital Markets Corp.
 KeyBanc
Capital Markets Inc.
 PNC Capital Markets LLC
 BBVA Securities
Inc.

		
	Pricing Date:	  	September 4, 2014.
		
	Trade Date:	  	September 4, 2014.
		
	Expected Settlement Date:	  	September 10, 2014.
		
	CUSIP Number:	  	447462 AA0.
		
	ISIN:	  	US447462AA02.
		
	Listing:	  	None.
		
	Concurrent Convertible Note Hedge Transactions and Warrant Transactions:	  	  
 In connection with the pricing of the notes, we entered into one or
more privately negotiated convertible note hedge transactions with Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P Morgan Securities LLC or their respective affiliates (in this capacity, the “hedge counterparties”). The
convertible note hedge transactions collectively cover, subject to customary anti-dilution adjustments, the number of shares of common stock that initially underlie the notes sold in the offering. We also entered into one or more separate, privately
negotiated warrant transactions with the hedge counterparties collectively relating to the same number of shares of our common stock, subject to customary anti-dilution adjustments. The warrants evidenced by the warrant transactions will be settled
on a net-share basis.
  
 The convertible note hedge transactions are intended to reduce
the potential dilution with respect to our common stock and/or offset any potential cash payments we are required to make in excess of the principal amount of converted notes, as the case may be, upon any conversion of the notes. The warrant
transactions could have a dilutive effect with respect to our common stock to the extent that the price per share of our common stock exceeds the strike price of the warrants evidenced by the warrant transactions. The strike price of the warrants
initially equals approximately $97.12 and is subject to customary anti-dilution adjustments.
  

If the initial purchasers exercise their option to purchase additional notes from us, we intend to enter into one or more additional convertible note hedge
transactions and one or more additional warrant transactions with the hedge counterparties, which will initially cover, collectively, the number of shares of our common stock that will initially underlie the additional notes we sell to the initial
purchasers.










			
		
		  	 See “Description of the Concurrent Convertible Note Hedge Transactions and Warrant Transactions” in the Preliminary Offering
Memorandum.

		
	Use of Proceeds:	  	 We estimate that the net proceeds from this offering will be approximately $218.3 million (or approximately $242.6 million if the
initial purchasers fully exercise their option to purchase additional notes), after deducting initial purchasers’ discounts and commissions and estimated expenses payable by us.

 
 We intend to use approximately $16.65 million of the net proceeds of this offering to fund
the cost of entering into the convertible note hedge transactions (after such cost is partially offset by the proceeds that we receive from entering into the warrant transactions). We also intend to use approximately $25 million of the net proceeds
of this offering to repurchase shares of our common stock concurrently with the pricing of this offering from purchasers of the notes.
  

We expect to use the remaining net proceeds from this offering for working capital and general corporate purposes. We may also use the net proceeds for one or
more acquisitions or other strategic transactions. However, we have no current commitments or obligations with respect to any acquisitions or other strategic transactions.
  

If the initial purchasers exercise their option to purchase additional notes, we intend to use a portion of the net proceeds to fund the net cost of entering
into the additional convertible note hedge transactions.
  
 See “Use of
Proceeds” in the Preliminary Offering Memorandum.

		
	 Description of Notes—Conversion

Rights—Increase to Conversion Rate
 Upon a
Conversion in Connection With a
 Make-Whole Fundamental Change:
	  	

 The following table sets forth the stock prices and effective dates and the number of additional shares, if
any, by which the conversion rate will be increased for a holder that converts a note in connection with a make-whole fundamental change having such stock price and effective date: 

																																																									
	 	 	Stock Price	 
	 Effective Date
	 	$62.66	 	 	$65.00	 	 	$67.50	 	 	$70.00	 	 	$75.00	 	 	$79.89	 	 	$90.00	 	 	$100.00	 	 	$125.00	 	 	$150.00	 	 	$175.00	 	 	$200.00	 	 	$250.00	 	 	$300.00	 
	 September 10, 2014
	 	 	3.4420	  	 	 	3.1376	  	 	 	2.8486	  	 	 	2.5916	  	 	 	2.1578	  	 	 	1.8178	  	 	 	1.3052	  	 	 	0.9681	  	 	 	0.5134	  	 	 	0.3095	  	 	 	0.2029	  	 	 	0.1437	  	 	 	0.0783	  	 	 	0.0428	  
	 October 1, 2015
	 	 	3.4420	  	 	 	3.1811	  	 	 	2.8666	  	 	 	2.5881	  	 	 	2.1210	  	 	 	1.7578	  	 	 	1.2201	  	 	 	0.8762	  	 	 	0.4351	  	 	 	0.2523	  	 	 	0.1641	  	 	 	0.1169	  	 	 	0.0640	  	 	 	0.0349	  
	 October 1, 2016
	 	 	3.4420	  	 	 	3.1992	  	 	 	2.8543	  	 	 	2.5497	  	 	 	2.0430	  	 	 	1.6542	  	 	 	1.0919	  	 	 	0.7469	  	 	 	0.3369	  	 	 	0.1865	  	 	 	0.1225	  	 	 	0.0879	  	 	 	0.0490	  	 	 	0.0268	  
	 October 1, 2017
	 	 	3.4420	  	 	 	3.1536	  	 	 	2.7709	  	 	 	2.4347	  	 	 	1.8819	  	 	 	1.4660	  	 	 	0.8881	  	 	 	0.5580	  	 	 	0.2154	  	 	 	0.1157	  	 	 	0.0788	  	 	 	0.0583	  	 	 	0.0335	  	 	 	0.0183	  
	 October 1, 2018
	 	 	3.4420	  	 	 	2.9626	  	 	 	2.5276	  	 	 	2.1487	  	 	 	1.5376	  	 	 	1.0976	  	 	 	0.5413	  	 	 	0.2775	  	 	 	0.0839	  	 	 	0.0516	  	 	 	0.0385	  	 	 	0.0296	  	 	 	0.0174	  	 	 	0.0094	  
	 October 1, 2019
	 	 	3.4420	  	 	 	2.8675	  	 	 	2.2977	  	 	 	1.7686	  	 	 	0.8162	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  	 	 	—  	  

 The exact stock prices and effective dates may not be set forth in the table above, in which case: 

 

	 	•	 	if the stock price is between two stock prices listed in the table or the effective date is between two effective dates listed in the table, the number of additional shares will be determined by a straight-line
interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier and later effective dates based on a 365- or 366-day year, as applicable; 


 

	 	•	 	if the stock price is greater than $300.00 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above), no additional shares will be added to the
conversion rate; and 

  

	 	•	 	if the stock price is less than $62.66 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above), no additional shares will be added to the conversion
rate. 

 Notwithstanding the foregoing, in no event will the conversion rate exceed 15.9590 shares per $1,000 principal amount of notes,
subject to adjustment at the same time and in the same manner as the conversion rate as set forth in the Preliminary Offering Memorandum under the caption “Description of Notes—Conversion Rights—Conversion Rate Adjustments.” 








 Our obligation to increase the conversion rate as described above could be considered a penalty, in which case
the enforceability thereof would be subject to general principles of reasonableness and equitable remedies. 
  

 
 This communication is
intended for the sole use of the person to whom it is provided by the sender. This material is confidential and is for your information only and is not intended to be used by anyone other than you. This information does not purport to be a complete
description of the notes or the offering. This communication does not constitute an offer to sell or the solicitation of an offer to buy any notes in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. 
 The offer and sale of the notes and the shares of common stock, if any, issuable upon conversion of the notes have not been and will
not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws. Accordingly, the notes and such shares may not be offered or sold within the United States or to U.S. persons or in
any other jurisdiction, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. The initial purchasers are initially offering the notes
only to qualified institutional buyers as defined in, and in reliance on, Rule 144A under the Securities Act. 
 The notes and the shares of
common stock, if any, issuable upon conversion of the notes are not transferable except in accordance with the restrictions described in the Preliminary Offering Memorandum under the caption “Notice to Investors.” 

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. 







 SCHEDULE C 

Issuer Written Information 
 Final Term
Sheet in the form set forth on Schedule B 

  
 Sch C - 1 








 SCHEDULE D 

List of Persons and Entities Subject to Lock-up 

Directors 
 DuBose Ausley 

James B. Edwards 
 H. Eugene Lockhart 

George E. Massaro 
 John McCartney 

John S. Moody 
 Executive Officers 

C. Mark Hussey 
 Diane E. Ratekin 

James H. Roth 

  
 Sch D - 1 








 Exhibit A-1 

FORM OF OPINION OF COMPANY’S COUNSEL 

TO BE DELIVERED PURSUANT TO SECTION 5(a) 

[See attached] 

  
 A1-1 








 Exhibit A-2 

FORM OF NEGATIVE ASSURANCE LETTER OF COMPANY’S COUNSEL 

TO BE DELIVERED PURSUANT TO SECTION 5(a) 

[See attached] 

  
 A2-1 








 Exhibit B 

FORM OF LOCK-UP TO BE DELIVERED PURSUANT TO SECTION 5(g) 

September
[ l ], 2014 

Merrill Lynch, Pierce, Fenner & Smith 

Incorporated 
 J.P. Morgan Securities LLC 

as Representatives of the several 

Initial Purchasers to be named in the 

within-mentioned Purchase Agreement 

c/o Merrill Lynch, Pierce, Fenner & Smith 

Incorporated 
 One Bryant Park 

New York, New York 10036 
 Re: Proposed
Offering by Huron Consulting Group Inc. 
 Dear Sirs: 

The undersigned understands that Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and J.P. Morgan
Securities LLC (“J.P. Morgan”) propose to enter into a Purchase Agreement (the “Purchase Agreement”) with the Company providing for the offering of up to $250,000,000 aggregate principal amount of the Company’s Convertible
Senior Notes (the “Securities”). In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder and an officer and/or director of the Company, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each initial purchaser to be named in the Purchase Agreement that, during the period beginning on the date hereof and ending on the date that is 60 days from the
date of the Purchase Agreement (the “Lock-Up Period”), the undersigned will not, without the prior written consent of Merrill Lynch and J.P. Morgan, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Company’s common stock, par value $0.01 per share (the “Common
Stock”), or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition
(collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of
1933, as amended, or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or
transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise. 

  
 B-1 








 Notwithstanding the foregoing, the undersigned may transfer the Lock-Up Securities without the
prior written consent of Merrill Lynch and J.P. Morgan in the following circumstances: 
  

	 	(i)	as a bona fide gift or gifts; 

  

	 	(ii)	to any trust, limited liability company, limited partnership or other estate planning vehicle for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this
lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); 

  

	 	(iii)	as a distribution to limited partners or stockholders of the undersigned; 

  

	 	(iv)	to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned; 

  

	 	(v)	transfers to the Company to satisfy tax withholding obligations that become due during the Lock-Up Period upon vesting of previously issued restricted stock awards or restricted stock units; provided that, if the
undersigned is required to file a report under the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the term of this lock-up agreement related to such disposition of shares of Common Stock to the Company by
the undersigned solely to satisfy tax withholding obligations, the undersigned shall include a statement in such report to the effect that the filing relates to the satisfaction of tax withholding obligations of the undersigned in connection with
the vesting of restricted stock awards or restricted stock units; 

  

	 	(vi)	the sale pursuant to any contract, instruction or plan established prior to the date hereof that satisfies all of the requirements of Rule 10b5-1 (a “10b-5 Plan”) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”); provided this exception to the lock-up restrictions is referred to in the General Disclosure Package and the Final Offering Memorandum (in each case, as defined in the Purchase Agreement); 


 

	 	(vii)	the establishment of any 10b5-1 Plan, provided that no sales of Lock-Up Securities or securities convertible into, or exchangeable or exercisable for Lock-Up Securities, shall be made pursuant to a 10b5-1 Plan prior to
the expiration of the Lock-Up Period if such 10b5-1 Plan was established after the date hereof; provided, that such 10b5-1 Plan may only be established if no public announcement of the establishment or the existence thereof, and no filing with the
Securities and Exchange Commission or any other regulatory authority shall be required or shall be made voluntarily by the undersigned, the Company or any other person, prior to the expiration of the Lock-Up Period; or 


 

	 	(viii)	the transfer or intestate succession to the legal representatives or a member of the immediate family of the undersigned upon death of the undersigned; 


provided, in the case of clauses (i)-(v), (vii) and (viii) above, that (1) Merrill Lynch and J.P. Morgan receive a signed
lock-up agreement for the balance of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2) except as contemplated by clauses (v) and (vi) above, any such transfer shall not involve a
disposition for value, (3) except as contemplated by clauses (v) and (vi) above, such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16 of the Exchange
Act, and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers. 

Furthermore, the undersigned may sell shares of Common Stock of the Company purchased by the undersigned on the open market following the
offering if and only if (i) such sales are not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise and (ii) the undersigned does not otherwise voluntarily effect any public filing or
report regarding such sales. 

  
 B-2 








 The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. 

This Lock-Up Agreement shall lapse and become null and void if (i) the offering shall not have occurred on or before September 30,
2014, (ii) prior to the execution of the Purchase Agreement by the parties thereto, either the Representatives notify the Company, or the Company notifies the Representatives, in writing, that they do not intend to proceed with the offering, or
(iii) the Purchase Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder. 

 

			
	 Very truly yours,

	
	
Signature:                       
                                         
                   

	
	 Print
Name:                                        
                                       





  
 B-3